• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.240 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
December 29, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
December 16, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
December 12, 2025
From ImmunityBio
Via Business Wire
News headline image
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
November 13, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
November 04, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
September 08, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
August 26, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
August 19, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
August 13, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
August 11, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
August 05, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
July 25, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
July 25, 2025
From ImmunityBio, Inc.
Via Business Wire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
July 07, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
June 03, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
June 02, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
May 27, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
May 12, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
May 05, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
April 28, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
April 21, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
April 15, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
April 08, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
April 07, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio to Host Investor Day
March 26, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
March 13, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
March 03, 2025
From ImmunityBio, Inc.
Via Business Wire
News headline image
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
February 27, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap